High CD33 expression in NPM1-mut AMLs provided a rationale supporting the evaluation of the drug-conjugated anti-CD33 antibody gentuzumab ozogamicin (GO) in this AML subtype. This evidence concerns the gene NPM1 and acute myeloid leukemia.